Treating Metastatic NSCLC: Choosing the Best Treatment for Optimal Outcomes

A 55-year-old mom and high school teacher who received lorlatinib for ALK+ NSCLC with brain metastases.

Medical experts discuss strategies for patient education on managing potential adverse events of lorlatinib and other ALK inhibitors, emphasizing what to expect and when to contact the care team.

Key opinion leaders discuss strategies for managing neurotoxicity with lorlatinib and other ALK inhibitors, including monitoring adverse events and balancing symptom management with treatment efficacy.

An expert discussion surrounding experience with managing weight gain and gastrointestinal adverse events associated with lorlatinib, addressing quality of life, symptom mitigation strategies, and maintaining treatment efficacy.

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, highlighting multidisciplinary management strategies and integrating best practices into electronic medical records.

Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, discussing unique challenges and benefits observed in clinical practice.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

Medical experts discuss strategies for managing adverse events associated with KRAS-targeted therapies, addressing monitoring challenges with oral medications and balancing symptom management with treatment efficacy.

Medical experts provide their final insights surrounding quality of life amid treatment for metastatic non-small cell lung cancer.